Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Sunday, October 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus reported promising early Phase 2 results from the NEOASIS study, focusing on dMMR colon cancer. In this study, 72% of patients had no cancer remaining at surgery after receiving a combination of botensilimab and balstilimab. This research was conducted in collaboration with the Netherlands Cancer Institute.

Market Sentiment Analysis

POSITIVE FACTORS

  • 72% of patients had no cancer remaining at surgery.
  • Results come from a Phase 2 study.
  • Combination therapy shows promise in dMMR colon cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
5.5%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Balstilimab
Phase 3 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery

Frequently Asked Questions

What were the results of the NEOASIS study?

The study found that 72% of patients had no cancer remaining at surgery.

What drugs were evaluated in the study?

The study evaluated botensilimab and balstilimab.

Who sponsored the NEOASIS study?

The Netherlands Cancer Institute sponsored the study.

What type of cancer was targeted in the study?

The study focused on mismatch repair-deficient colon cancer.

ShareAdd on Google
Tags: AGEN Agenus dMMR colon cancer NEOASIS study botensilimab balstilimab
Last updated: Oct 25, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BalstilimabPhase 3
Colorectal Cancer →

Catalyst track record

+203%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →